RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arch Therapeutics Stock

Arch Therapeutics EBIT 2024

Arch Therapeutics EBIT

120.43 M USD

Ticker

ARTH

ISIN

US03939W1099

WKN

A1W2JT

In 2024, Arch Therapeutics's EBIT was 120.43 M USD, a -2,487.36% increase from the -5.04 M USD EBIT recorded in the previous year.

The Arch Therapeutics EBIT history

YEAREBIT (undefined USD)
2026e294.91
2025e197.2
2024e120.43
2023-5.04
2022-5.71
2021-6.38
2020-5.35
2019-6.37
2018-7.45
2017-7.3
2016-6.05
2015-5.46
2014-4.61
2013-1.74
2012-0.42
2011-0.01

Arch Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arch Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arch Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arch Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arch Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arch Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arch Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arch Therapeutics’s growth potential.

Arch Therapeutics Revenue, EBIT and net profit per share

DateArch Therapeutics RevenueArch Therapeutics EBITArch Therapeutics Net Income
2026e335.46 M undefined294.91 M undefined68.52 M undefined
2025e226.39 M undefined197.2 M undefined47.05 M undefined
2024e140.76 M undefined120.43 M undefined112.18 M undefined
202375,720 undefined-5.04 M undefined-6.98 M undefined
202220,000 undefined-5.71 M undefined-5.28 M undefined
202110,000 undefined-6.38 M undefined-6.24 M undefined
20200 undefined-5.35 M undefined-4.69 M undefined
20190 undefined-6.37 M undefined-4.55 M undefined
20180 undefined-7.45 M undefined-4.81 M undefined
20170 undefined-7.3 M undefined-7.79 M undefined
20160 undefined-6.05 M undefined-5.99 M undefined
20150 undefined-5.46 M undefined-2.95 M undefined
20140 undefined-4.61 M undefined-8.14 M undefined
20130 undefined-1.74 M undefined-1.85 M undefined
20120 undefined-420,000 undefined-580,000 undefined
20110 undefined-10,000 undefined-10,000 undefined

Arch Therapeutics stock margins

The Arch Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arch Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arch Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arch Therapeutics's sales revenue. A higher gross margin percentage indicates that the Arch Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arch Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arch Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arch Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arch Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arch Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arch Therapeutics Margin History

Arch Therapeutics Gross marginArch Therapeutics Profit marginArch Therapeutics EBIT marginArch Therapeutics Profit margin
2026e-3.22 %87.91 %20.43 %
2025e-3.22 %87.11 %20.78 %
2024e-3.22 %85.56 %79.69 %
2023-3.22 %-6,662.03 %-9,221.92 %
2022-200 %-28,550 %-26,400 %
2021-100 %-63,800 %-62,400 %
2020-3.22 %0 %0 %
2019-3.22 %0 %0 %
2018-3.22 %0 %0 %
2017-3.22 %0 %0 %
2016-3.22 %0 %0 %
2015-3.22 %0 %0 %
2014-3.22 %0 %0 %
2013-3.22 %0 %0 %
2012-3.22 %0 %0 %
2011-3.22 %0 %0 %

Arch Therapeutics Aktienanalyse

What does Arch Therapeutics do?

Arch Therapeutics Inc. is a Massachusetts-based company specializing in the development of medical devices. The company was founded in 2006 and has expanded its activities to manufacturing innovative medical products that can be used in various surgical procedures. The business model of Arch Therapeutics is based on the development of medical devices that aim to enable faster recovery for patients. The company utilizes a patented technology platform called "AC5" for the manufacturing and marketing of devices for various medical applications. The company has various divisions specializing in different medical applications. One main focus is the development of devices for hemostasis (blood clotting) in surgery, which is currently in the testing phase. Arch Therapeutics aims to provide a better alternative to existing solutions such as surgical clips or sutures, which are often associated with undesirable side effects. Another focus of Arch Therapeutics is the manufacturing of devices for dermatology. The company has developed a technology that enables a new and unique process for the rapid healing of wounds. This process is especially relevant for the treatment of difficult-to-heal wounds and chronic wounds. The company also has a division for ophthalmic surgery, which has developed a patented device technology for the treatment of glaucoma-related issues. This technology is intended to be a better alternative to conventional treatment methods such as eye drops. Arch Therapeutics' portfolio includes a wide range of medical devices and solutions for various medical applications. These products are designed to enable better patient recovery and have been developed by a group of experts, ensuring high quality and effectiveness. The offered products also include dermatology products, adhesion barriers, surgical J-clips, as well as wound closure and hemostasis devices. Overall, Arch Therapeutics has a strong potential for growth and expansion in the medical device industry. The company has already obtained patents for its AC5 platform and developed a wide range of products for various medical applications. With a dedicated team of employees, the company has laid a strong foundation for its future and is expected to remain a leading provider of medical devices in the coming years. Arch Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Arch Therapeutics's EBIT

Arch Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Arch Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Arch Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Arch Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Arch Therapeutics stock

How much did Arch Therapeutics achieve in EBIT for the current year?

In the current year, Arch Therapeutics has achieved an EBIT of 120.43 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Arch Therapeutics.

How has the EBIT of Arch Therapeutics developed in recent years?

The EBIT of Arch Therapeutics has increased by -2,487.357% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Arch Therapeutics?

The EBIT of Arch Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Arch Therapeutics pay?

Over the past 12 months, Arch Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arch Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Arch Therapeutics?

The current dividend yield of Arch Therapeutics is .

When does Arch Therapeutics pay dividends?

Arch Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arch Therapeutics?

Arch Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Arch Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arch Therapeutics located?

Arch Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arch Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arch Therapeutics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Arch Therapeutics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Arch Therapeutics in the year 2023?

In the year 2023, Arch Therapeutics distributed 0 USD as dividends.

In which currency does Arch Therapeutics pay out the dividend?

The dividends of Arch Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arch Therapeutics

Our stock analysis for Arch Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arch Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.